Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CCXI's Cash to Debt is ranked higher than
83% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. CCXI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CCXI' s Cash to Debt Range Over the Past 10 Years
Min: 61.8  Med: 125.84 Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 5.53
M-Score: -4.20
WACC vs ROIC
15.87%
-266.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -52.22
CCXI's ROE (%) is ranked lower than
63% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. CCXI: -52.22 )
Ranked among companies with meaningful ROE (%) only.
CCXI' s ROE (%) Range Over the Past 10 Years
Min: -52.24  Med: -33.61 Max: -4.02
Current: -52.22
-52.24
-4.02
ROA (%) -48.67
CCXI's ROA (%) is ranked lower than
69% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. CCXI: -48.67 )
Ranked among companies with meaningful ROA (%) only.
CCXI' s ROA (%) Range Over the Past 10 Years
Min: -48.48  Med: -31.50 Max: -3.07
Current: -48.67
-48.48
-3.07
ROC (Joel Greenblatt) (%) -4402.60
CCXI's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. CCXI: -4402.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CCXI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4421.79  Med: -2689.25 Max: -22.36
Current: -4402.6
-4421.79
-22.36
Revenue Growth (3Y)(%) -100.00
CCXI's Revenue Growth (3Y)(%) is ranked lower than
99% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CCXI: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CCXI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: -100
Current: -100
EBITDA Growth (3Y)(%) -0.30
CCXI's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. CCXI: -0.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CCXI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: -0.3
Current: -0.3
EPS Growth (3Y)(%) -1.50
CCXI's EPS Growth (3Y)(%) is ranked higher than
52% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CCXI: -1.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CCXI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: -1.5
Current: -1.5
» CCXI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CCXI Guru Trades in Q1 2015

Jim Simons 81,700 sh (+27.81%)
Chuck Royce 70,000 sh (unchged)
» More
Q2 2015

CCXI Guru Trades in Q2 2015

Steven Cohen 400 sh (New)
Jim Simons 127,377 sh (+55.91%)
Chuck Royce 70,000 sh (unchged)
» More
Q3 2015

CCXI Guru Trades in Q3 2015

Steven Cohen Sold Out
Chuck Royce 55,000 sh (-21.43%)
Jim Simons 24,700 sh (-80.61%)
» More
Q4 2015

CCXI Guru Trades in Q4 2015

Steven Cohen 19,400 sh (New)
Jim Simons 44,300 sh (+79.35%)
Chuck Royce 33,300 sh (-39.45%)
» More
» Details

Insider Trades

Latest Guru Trades with CCXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.44
CCXI's P/B is ranked higher than
82% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. CCXI: 1.44 )
Ranked among companies with meaningful P/B only.
CCXI' s P/B Range Over the Past 10 Years
Min: 0.86  Med: 2.64 Max: 4.98
Current: 1.44
0.86
4.98
Current Ratio 13.11
CCXI's Current Ratio is ranked higher than
83% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CCXI: 13.11 )
Ranked among companies with meaningful Current Ratio only.
CCXI' s Current Ratio Range Over the Past 10 Years
Min: 6.49  Med: 9.25 Max: 19.54
Current: 13.11
6.49
19.54
Quick Ratio 13.11
CCXI's Quick Ratio is ranked higher than
84% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. CCXI: 13.11 )
Ranked among companies with meaningful Quick Ratio only.
CCXI' s Quick Ratio Range Over the Past 10 Years
Min: 6.49  Med: 9.25 Max: 19.54
Current: 13.11
6.49
19.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.60
CCXI's Price/Net Cash is ranked higher than
89% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. CCXI: 1.60 )
Ranked among companies with meaningful Price/Net Cash only.
CCXI' s Price/Net Cash Range Over the Past 10 Years
Min: 1.97  Med: 4.47 Max: 5.44
Current: 1.6
1.97
5.44
Price/Net Current Asset Value 1.59
CCXI's Price/Net Current Asset Value is ranked higher than
90% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. CCXI: 1.59 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CCXI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.95  Med: 4.40 Max: 5.4
Current: 1.59
1.95
5.4
Price/Tangible Book 1.45
CCXI's Price/Tangible Book is ranked higher than
86% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CCXI: 1.45 )
Ranked among companies with meaningful Price/Tangible Book only.
CCXI' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.71  Med: 3.17 Max: 4.94
Current: 1.45
1.71
4.94
Earnings Yield (Greenblatt) (%) -140.52
CCXI's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. CCXI: -140.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CCXI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -170.19  Med: 0.00 Max: 0
Current: -140.52
-170.19
0

More Statistics

Revenue(Mil) $6
EPS $ -1.08
Beta1.87
Short Percentage of Float11.21%
52-Week Range $2.16 - 9.46
Shares Outstanding(Mil)44.29

Business Description

Industry: Biotechnology » Biotechnology
Compare:TPE:1734, ASX:VLA, NAS:AFMD, NAS:DPRX, XPAR:CEREN, TSX:HBP » details
Traded in other countries:2CX.Germany,
Chemocentryx Inc was incorporated in the state of Delaware on November 8, 1996. The Company is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. It currently has five drug candidates in clinical development. CCX168 —Targeting the chemoattractant receptor known as C5aR, CCX168 has successfully completed and reported positive clinical data from the first two steps of a three-step Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA, associated renal vasculitis, or AARV. CCX140 — Targeting the chemokine receptor known as CCR2, CCX140 is currently in Phase II clinical development in patients with diabetic nephropathy, a form of kidney disease. Vercirnon (also known as Traficet-EN, or CCX282) —Targeting the chemokine receptor known as CCR9, vercirnon is its drug candidate for the treatment of patients with moderate-to-severe Crohn's disease. CCX872 — its second generation orally administered inhibitor targeting CCR2, CCX872 is expected to complete Phase I clinical development. CCX507 — its second generation CCR9 inhibitor for the treatment of inflammatory bowel disease, or IBD, CCX507 is expected to complete Phase I clinical development. Its current drug candidates are manufactured using common chemical engineering and synthetic processes from readily available raw materials. It rely on contract manufacturing organizations to produce its drug candidates in accordance with the FDA's current good manufacturing practices, or cGMP, regulations for use in its clinical trials. The Company competes in the pharmaceutical, biotechnology and other related markets that address AARV, chronic kidney disease and diabetic nephropathy, IBD, rheumatoid arthritis, other autoimmune diseases and inflammatory disorders, and cancer. The Company competes with the pharmaceutical companies that currently sell or are developing drugs include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bayer, Bristol-Myers Squibb, Elan, Roche/Genentech, GSK, Johnson & Johnson, Merck, Merck Serono, Takeda, Novartis, Pfizer, Sanofi and Teva. The Company and its manufacturers are subject to federal, state and local and foreign laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for CCXI

Headlines

Articles On GuruFocus.com
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 

More From Other Websites
ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a... Apr 28 2016
ChemoCentryx Announces Immuno-Oncology Data Presentation at the American Association for Cancer... Apr 18 2016
5 Stocks Poised for Big Breakouts Apr 01 2016
CHEMOCENTRYX, INC. Financials Mar 18 2016
Edited Transcript of CCXI earnings conference call or presentation 14-Mar-16 9:00pm GMT Mar 15 2016
ChemoCentryx reports 4Q loss Mar 14 2016
ChemoCentryx reports 4Q loss Mar 14 2016
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 14 2016
ChemoCentryx Reports Fourth Quarter 2015 Financial Results and Provides Corporate Update Mar 14 2016
Q4 2015 ChemoCentryx Inc Earnings Release - After Market Close Mar 14 2016
CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 09 2016
ChemoCentryx to Hold Fourth Quarter 2015 Financial Results Conference Call on Monday, March 14, 2016 Feb 29 2016
ChemoCentryx to Present at the Cowen and Company 36th Annual Healthcare Conference Feb 25 2016
ChemoCentryx (CCXI) Rises: Stock Adds 8.2% in Session Feb 10 2016
ChemoCentryx rare-disease drug as effective as standard of care Jan 06 2016
ChemoCentryx drug meets main goal in mid-stage study Jan 06 2016
Biotechnology Equities Update -- Arena Pharma, Compugen, ChemoCentryx, and Concert Pharma Dec 23 2015
A Change in Tides - Analyst Notes on Hemisphere Media Group, AngioDynamics, ChemoCentryx and... Dec 17 2015
What Do Hedge Funds Think of Blount International, Inc. (BLT)? Dec 02 2015
ChemoCentryx (CCXI) Shares March Higher, Can It Continue? Dec 02 2015
Hedge Funds Are Crazy About Panhandle Oil and Gas Inc. (PHX) Nov 30 2015
Hedge Funds Are Selling Navios Maritime Holdings Inc. (NM) Nov 26 2015
What Makes a Chart Move? – Research on Zix, DavidsTea, ChemoCentryx and Genie Energy Nov 18 2015
ChemoCentryx reports 3Q loss Nov 09 2015
ChemoCentryx reports 2Q loss Aug 06 2015
ChemoCentryx reports 4Q loss Mar 12 2015
ChemoCentryx posts 3Q loss Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK